Coda Octopus Group, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coda Octopus Group, Inc. (Nasdaq: CODA) on July 6, 2026, reporting events occurring on July 1, 2026. The filing addresses significant changes in the Company's executive leadership, specifically within the finance function.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
- Departure of Interim CFO: Gayle Jardine, Interim Chief Financial Officer, will retire effective August 3, 2026.
- Appointment of New CFO: Mark Kelly has been appointed as Chief Financial Officer, effective August 3, 2026.
- Probationary Period: Mr. Kelly's appointment is subject to a three-month probationary period, which may be extended by an additional two months at the Company's discretion.
Management Commentary, Compensation, and Risks
Executive Background: Mr. Kelly brings experience from Medac Pharma (Finance Director, 2024-2025), Chubb Insurance (Head of Glasgow Finance, 2022-2024), Twist Bioscience Corp. (Finance Director, 2021-2022), and Charles River Laboratories (Senior Finance Director and European Controller, 2016-2021). He is a Chartered Accountant qualified in 1996.
Compensation Package:
- Base Salary: £165,000 annually (approximately $218,625 USD based on an exchange rate of $1.325).
- Bonus: Eligible for annual bonuses at the Company's discretion.
- Equity: A restricted stock grant valued at $40,000, vesting in two equal annual installments commencing October 31, 2027, subject to performance milestones.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond the standard transition risks associated with executive turnover.
Key Facts for Investor Verification
- Confirm the effective date of the CFO transition (August 3, 2026) and the duration of the probationary period.
- Verify the vesting schedule and specific performance milestones attached to the $40,000 restricted stock grant.
- Monitor future filings for the formal announcement of the new CFO's first full quarter of leadership.
- Note that this filing contains no updated financial results; investors should refer to the most recent 10-Q or 10-K for financial data.